Manns M - Search Results

1

NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis.

Kühnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, Kubicka S. Kühnel F, et al. Among authors: manns m. J Biol Chem. 2000 Mar 3;275(9):6421-7. doi: 10.1074/jbc.275.9.6421. J Biol Chem. 2000. PMID: 10692445 Free article.

2

p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis.

Kubicka S, Kühnel F, Zender L, Rudolph KL, Plümpe J, Manns M, Trautwein C. Kubicka S, et al. Among authors: manns m. J Biol Chem. 1999 Nov 5;274(45):32137-44. doi: 10.1074/jbc.274.45.32137. J Biol Chem. 1999. PMID: 10542249 Free article.

3

Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.

Kubicka S, Trautwein C, Niehof M, Manns M. Kubicka S, et al. Among authors: manns m. Hepatology. 1997 Apr;25(4):867-73. doi: 10.1002/hep.510250414. Hepatology. 1997. PMID: 9096590

4

Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure.

Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. Streetz K, et al. Among authors: manns m. Gastroenterology. 2000 Aug;119(2):446-60. doi: 10.1053/gast.2000.9364. Gastroenterology. 2000. PMID: 10930380

5

Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area.

Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, Manns M. Kubicka S, et al. Among authors: manns m. Liver. 2000 Jul;20(4):312-8. doi: 10.1034/j.1600-0676.2000.020004312.x. Liver. 2000. PMID: 10959810

6

VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.

Schache P, Gürlevik E, Strüver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Kühnel F, Kubicka S. Schache P, et al. Among authors: manns m. Gene Ther. 2009 Jul;16(7):849-61. doi: 10.1038/gt.2009.39. Epub 2009 Apr 16. Gene Ther. 2009. PMID: 19369968

7

Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.

Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Kubicka S, et al. Among authors: manns m. Hepatogastroenterology. 2001 May-Jun;48(39):783-9. Hepatogastroenterology. 2001. PMID: 11462924 Clinical Trial.

8

Clinical relevance of mutations in the precore genome of the hepatitis B virus.

Tillmann H, Trautwein C, Walker D, Michitaka K, Kubicka S, Böker K, Manns M. Tillmann H, et al. Among authors: manns m. Gut. 1995 Oct;37(4):568-73. doi: 10.1136/gut.37.4.568. Gut. 1995. PMID: 7489947 Free PMC article.

9

Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event.

Kubicka S, Trautwein C, Schrem H, Tillmann H, Manns M. Kubicka S, et al. Among authors: manns m. J Hepatol. 1995 Oct;23(4):412-9. doi: 10.1016/0168-8278(95)80199-5. J Hepatol. 1995. PMID: 8655958

10

K-ras mutations in the bile of patients with primary sclerosing cholangitis.

Kubicka S, Kühnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, Manns M, Meier PN. Kubicka S, et al. Among authors: manns m. Gut. 2001 Mar;48(3):403-8. doi: 10.1136/gut.48.3.403. Gut. 2001. PMID: 11171833 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,824 results

Search Page

Filters